TITLE

Progress reports in the battle against acquired immune deficiency syndrome

PUB. DATE
April 1989
SOURCE
FDA Consumer;Apr89, Vol. 23 Issue 3, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Provides an update on progress being made in fight against acquired immune deficiency syndrome (AIDS). U.S. Food and Drug Administration (FDA) approved wider use of aerosolized pentamidine to prevent pneumonia in AIDS patients; Studies expended for drug foscarnet used to treat cytomegalovirus (CVM) retinitis which often afflicts AIDS victims.
ACCESSION #
8905290429

 

Related Articles

  • Sports groups review HIV policies. A.S. // Physician & Sportsmedicine;Nov92, Vol. 20 Issue 11, p15 

    Lists medical and sports organizations addressing questions and public's concerns on the human immunodeficiency virus (HIV). American Medical Society for Sports Medicine in Middleton, Wis.; American Orthopaedic Society for Sports Medicine in Des Plaines, Ill.; American College of Sports Medicine...

  • Towards a vaccine against AIDS. Vieillard, Vincent; Dereuddre-Bosquet, Nathalie; Corneau, Aurélien; Mangeot-Méderle, Isabelle; Fausther-Bovendo, Hugues; Grand, Roger Le; Debre, Patrice // Retrovirology;2010 Supplement 1, Vol. 7, p1 

    An abstract of the article "Towards a Vaccine Against AIDS," by Vincent Vieillard, Nathalie Dereuddre-Bosquet, Aurélien Corneau, Isabelle Mangeot-Méderle, Hugues Fausther-Bovendo, Roger Le Grand and Patrice Debre is presented.

  • AIDS as a clinically curable disease: The growing optimism. Gallo, Robert C. // AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p7 

    Suggest that AIDS might be a clinically curable disease. Effects of chemotherapy; Advances in chemotherapy compared with other HIV enzymes; Replication of HIV; Approaches to minimizing toxicity.

  • Didanosine toxicity.  // AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p50 

    Reports on the tolerance of AIDS patients to the drug didanosine. Toxicity of didanosine; Comparison to other drugs; What studies have shown.

  • Editorial. Laurence, Jeffrey // AIDS Patient Care & STDs;Aug96, Vol. 10 Issue 4, p208 

    Editorial. Comments on the effects of the prolonged drug development and approval processes on the growing incidence of AIDS among women in the United States. Wider availability of novel agents early in drug development; Unrecognized sexually transmitted diseases as a cause of marked increase...

  • Editorial. Laurence, Jeffrey // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p278 

    Editorial. Expresses concern and hope on the developments of AIDS treatment based on reports in the Eleventh International AIDS Conference. Longer lives for compliant users of multidrug antiviral regimens; Absence of documented complete destruction of virus; Treatment costs as enormous;...

  • Public policy update: An AmFAR report. Silver, Jane // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p304 

    Features the AIDS Drug Assistance Program (ADAP), a prescription drug reimbursement programs for Americans with HIV/AIDS. History of ADAP and its goals; Funds from support groups; Need for additional federal funding; Medical insurance coverages as the only recourse upon implementation of Health...

  • Triple therapy in previously untreated patients reduces viral load below limit of detection.  // AIDS Patient Care & STDs;Oct96, Vol. 10 Issue 5, p308 

    Presents results of triple drug regimen in previously untreated AIDS patients. Sustained one year reduction in viral load below levels of detection; Use of protease inhibitors not absolutely necessary; Significant improvements in CD4 cell counts; Percentage of mild to moderate rashes in...

  • Final CESARE trial results show continued clinical and survival benefit.  // AIDS Patient Care & STDs;Apr97, Vol. 11 Issue 2, p96 

    Discusses the results of the CESARE (Canada, Europe, South Africa, Australia) trial study on the efficacy and safety of adding 3TC and loviride, AZT plus ddl, AZT and ddC. Disease progression; Adverse effects of AIDS therapy.

  • New options in combination therapy reported from the Fourth Conference on Retroviruses and...  // AIDS Patient Care & STDs;Apr97, Vol. 11 Issue 2, p99 

    Reports on options in combination therapy presented at the Fourth Conference on Retroviruses and Opportunistic Infections. AZT and d4T, 3TC (nucleoside analog); DMP-226 (NNRTI) and indinavir; AZT, ddI, Nevirapine, and advanced disease; MKC-442.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics